Answers are grounded in this paper and cite their sources.
We present a case of a 75-year-old male patient who experienced a severe exacerbation of his Kaposi sarcoma lesions, which have remained clinically stable for a year, following treatment with BRAF/mitogen-activated protein kinase inhibitors for his coexisting melanoma. In this case, we present the possibility that BRAF/MEK inhibition may be mechanistically associated with the progression of Kaposi sarcoma and briefly discuss the potential mechanisms behind this phenomenon.
No takes yet. Share an insight, caveat, or question.
Tsimpidakis et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: